Baldwin Wealth Partners’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Baldwin Wealth Partners’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-38	Closed	-$1.69K	–	556
2024 Q3	$1.69K	Hold	38	–	–	﹤0.01%	968
2024 Q2	$1.57K	Hold	38	–	–	﹤0.01%	682
2024 Q1	$1.71K	Hold	38	–	–	﹤0.01%	649
2023 Q4	$1.73K	Hold	38	–	–	﹤0.01%	671
2023 Q3	$1.53K	Hold	38	–	–	﹤0.01%	689
2023 Q2	$1.82K	Hold	38	–	–	﹤0.01%	700
2023 Q1	$1.85K	Hold	38	–	–	﹤0.01%	732
2022 Q4	$1.9K	Buy	+38	New	+$1.96K	﹤0.01%	717

Other funds holding GNOM

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Baldwin Wealth Partners's GNOM Position: Q4 2024 in Review

Baldwin Wealth Partners sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q4 2024, closing a stake of 38 shares — an estimated $1.69K sold.

Baldwin Wealth Partners first reported a position in GNOM in Q4 2022 and held it in 8 quarters. The position peaked at $1.9K in Q4 2022. 68 funds tracked by Wall St. Rank hold GNOM as of Q4 2024.

Baldwin Wealth Partners reported no remaining Global X Genomics & Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
Baldwin Wealth Partners sold 38 Global X Genomics & Biotechnology ETF shares in Q4 2024, an estimated $1.69K.
Baldwin Wealth Partners first reported a position in Global X Genomics & Biotechnology ETF in Q4 2022 and held it in 8 quarters.
Baldwin Wealth Partners's Global X Genomics & Biotechnology ETF position peaked at $1.9K in Q4 2022.
68 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q4 2024.

Based on Baldwin Wealth Partners's 13F filing for Q4 2024, filed 22 Jan 2025.